Sichenzia Ross Friedman Ference LLP Advises DelMar Pharmaceuticals on $2.5M Registered Direct Offering
August 4, 2015 – Press Release – New York, NY – Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the Firm has represented DelMar Pharmaceuticals, Inc. (OTCQX: DMPI), a biopharmaceutical company focused on developing and commercializing cancer therapies, in a registered direct offering. DelMar accepted subscriptions from institutional and accredited investors and approximately 4.0 million common stock and warrants for an aggregate price of $2.5 million. Each common share had a purchase price of $0.60 per share. The warrants had an exercise price of $0.75 per share.
The Sichenzia Ross Friedman Ference LLP team was led by Partners Gregory Sichenzia, David Manno and Associate Jeffrey Cahlon.
- Founding Partner Gregory Sichenzia Quoted in Bankrate Article Discussing Prominent IPOs to Keep an Eye On - September 15, 2020
- Sichenzia Ross Ference LLP Represents Vuzix in $15.5 Million Registered Direct Offering - September 10, 2020
- Sichenzia Ross Ference LLP Represents Avinger Inc. in Close of $5.2 Million Underwritten Public Offering of Common Stock - August 26, 2020